AttayaSuvannasankhaMD

Oncology • Indianapolis, IN

Hematologic Oncology

Associate Professor, Medicine, Indiana University School of Medicine

Join to view full profile

Dr. Suvannasankha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Suvannasankha's full profile

Already have an account?

Office
1044 W Walnut St
# R4
Indianapolis, IN 46202
Phone+1 317-274-0843

Fax+1 317-274-0936

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2000 - 2003
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1997 - 2000
Chulalongkorn University Faculty of MedicineClass of 1996

Certifications & Licensure

IN State Medical License 2003 - 2025
PA State Medical License 1998 - 2000
American Board of Internal Medicine Hematology

Clinical Trials

Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma Start of enrollment: 2005 Jun 01
Terminated
Phase 2
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2007 Oct 01
Completed
Phase 2
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Role of Osteocytes in Myeloma Bone Disease Start of enrollment: 2014 Oct 07
Completed
A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy Start of enrollment: 2021 Dec 06
Withdrawn
Phase 2
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jan 23
RECRUITING
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

The American Federation for Medical Research maintains commitment to decades of support of vaccine and vaccination research to improve public health.
Zanthia Wiley, Sidharth Mahapatra, Gaurav Agarwal, Stephanie Baer, Syed Bukhari
Journal of Investigative Medicine. 2025-04-01
1 citations
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.
Kymberly D Watt, Stacey Rolak, David P Foley, Jennifer K Plichta, Sandhya Pruthi
Transplantation. 2024-12-01
1 citations
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke
Cancer. 2024-08-01

Press Mentions

First-in-Human Multiple Myeloma Study Shows 90 Percent Response RateApril 19th, 2023
Early Data Indicates New Therapy Is ‘Safe and Effective’ for Cancer Metastases in BonesApril 29th, 2021
Purdue Researchers at Work on Anemia App to Make Detection EasierNovember 30th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member